Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.
Press Releases
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°
October 21, 2020
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360° BASKING RIDGE, N.J. (October 21, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
October 8, 2020
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage Patient screening begins immediately at NYU Langone Health The study will explore the ability […]
Read MoreCaladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
October 7, 2020
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa BASKING RIDGE, N.J. (October 7, 2020) – Caladrius […]
Read MoreCaladrius Biosciences to Present at the BIO Investor Forum Digital
October 6, 2020
Caladrius Biosciences to Present at the BIO Investor Forum Digital BASKING RIDGE, N.J. (October 6, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), […]
Read MoreCaladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th
September 14, 2020
Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th BASKING RIDGE, N.J. (September 14, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum
September 10, 2020
Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum BASKING RIDGE, N.J. (September 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan
September 9, 2020
Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan Approval received from the Japan Patent Office to use HONEDRA® as brand name […]
Read MoreCaladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference
September 8, 2020
Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference BASKING RIDGE, N.J. (September 8, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020
September 3, 2020
Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020 BASKING RIDGE, N.J. (September 3, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time
August 27, 2020
Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time BASKING RIDGE, NJ / ACCESSWIRE / […]
Read MoreCaladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results
August 13, 2020
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results Clinical programs advanced and expanded with strengthened cash position Conference call begins today at […]
Read MoreCaladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020
August 6, 2020
Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020 BASKING RIDGE, N.J. (August 6, 2020) – Caladrius Biosciences, Inc. […]
Read MoreCaladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer
August 5, 2020
Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer BASKING RIDGE, N.J. (August 5, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors
July 28, 2020
Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors BASKING RIDGE, N.J. (July 28, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase
June 2, 2020
Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase BASKING RIDGE, N.J. (June 2, 2020) – […]
Read MoreCaladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 28, 2020
Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (May 28, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 26, 2020
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (May 26, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 14, 2020
Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions Single administration of CLBS16 durably improves heart function and […]
Read MoreCaladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results
May 7, 2020
Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and […]
Read MoreCaladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 6, 2020
Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions BASKING RIDGE, N.J. (May 6, 2020) – Caladrius […]
Read More